Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily in patients with chronic stable angina pectoris

INTERVENTION: A randomised, double‐blind, parallel‐group study in patients treated for 12 weeks ‐ Two arms: trimetazidine MR 80mg once daily or trimetazidine MR 35mg twice daily CONDITION: Angina pectoris attacks ; Circulatory System ; Angina pectoris PRIMARY OUTCOME: 1. Emergent adverse events ; 2. Blood pressure ; 3. Weight ; 4. Laboratory examinations: biochemical and haematological parameters ; 5.12‐lead electrocardiogram ; 6. CCS classification of symptoms of angina pectoris SECONDARY OUTCOME: No secondary outcome measures INCLUSION CRITERIA: 1. Male or female patient 2. More than or equal to 21 years old 3. Any ethnic origin 4. Patients with a prior diagnosis of stable angina pectoris of effort